Trial Profile

An Open-label, Comparative, Clinical Phase 1 Study to Assess the Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Typhoid conjugate vaccine EuBiologics (Primary) ; Typhoid vaccine Vi conjugate; Typhoid vaccine Vi-polysaccharide
Indications Typhoid
Focus Adverse reactions
Sponsors EuBiologics

Most Recent Events

10 Apr 2021 Results assessing the safety, tolerability, and immunogenicity of Vi-CRM197 in in healthy adults, published in the Vaccine
06 Dec 2019 Status changed from active, no longer recruiting to completed.
27 May 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com